Zelira Therapeutics Ltd has released a press release.
Insomnia Trial Meets Primary and Secondary Endpoints
Filed with ASX ·
6ix hasn’t read this filing yet.
Zelira Therapeutics Ltd. on 6ix
In the deck
Earlier from Zelira Therapeutics
- Appendix 4D & FY20 Interim Financial Report
- Phase 1 Opioid Reduction Clinical Trial Fully Enrolled
- Zelira Meets Primary Endpoints for Insomnia Trial
- Zelira Successfully Completes Capital Raising of $4.6M
- December 2019 Quarterly Report
Later from Zelira Therapeutics
- March 2020 Quarterly Report
- TasAlk to Manufacture Zeliras Insomnia and HOPE products
- Zelira Phase 1 Chronic Pain Trial Meets Clinical Endpoints
- Zelira Enters Deal to Develop Products For Vascular Diseases
- June 2020 Quarterly Report
Follow Zelira Therapeutics into a list and get an email when it puts out news.
Follow Zelira Therapeutics